WO2012006669A1 - Système et procédé permettant d'établir une stratégie personnelle d'intervention sur la santé - Google Patents
Système et procédé permettant d'établir une stratégie personnelle d'intervention sur la santé Download PDFInfo
- Publication number
- WO2012006669A1 WO2012006669A1 PCT/AU2011/000881 AU2011000881W WO2012006669A1 WO 2012006669 A1 WO2012006669 A1 WO 2012006669A1 AU 2011000881 W AU2011000881 W AU 2011000881W WO 2012006669 A1 WO2012006669 A1 WO 2012006669A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- data
- genetic profile
- objective data
- subjective
- Prior art date
Links
- 230000036541 health Effects 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000002068 genetic effect Effects 0.000 claims abstract description 47
- 235000016709 nutrition Nutrition 0.000 claims description 16
- 230000035764 nutrition Effects 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 238000004458 analytical method Methods 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 6
- 102100032752 C-reactive protein Human genes 0.000 claims description 5
- 101000787850 Homo sapiens Taste receptor type 2 member 38 Proteins 0.000 claims description 5
- 102100025867 Taste receptor type 2 member 38 Human genes 0.000 claims description 5
- 238000011872 anthropometric measurement Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 4
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims description 3
- 108010018924 Heme Oxygenase-1 Proteins 0.000 claims description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 3
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 claims description 3
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 claims description 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 3
- 102100035476 Serum paraoxonase/arylesterase 1 Human genes 0.000 claims description 3
- 102000008200 Uncoupling Protein 3 Human genes 0.000 claims description 3
- 108010021098 Uncoupling Protein 3 Proteins 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 3
- 108010019813 leptin receptors Proteins 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 102000009310 vitamin D receptors Human genes 0.000 claims description 3
- 108050000156 vitamin D receptors Proteins 0.000 claims description 3
- 102100031786 Adiponectin Human genes 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 claims description 2
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 claims description 2
- 101000941289 Homo sapiens Hepatic triacylglycerol lipase Proteins 0.000 claims description 2
- 238000008214 LDL Cholesterol Methods 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 2
- 230000037323 metabolic rate Effects 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- -1 CYPIAI Proteins 0.000 claims 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims 1
- 102100030461 Alpha-ketoglutarate-dependent dioxygenase FTO Human genes 0.000 claims 1
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 claims 1
- 102100033715 Apolipoprotein A-I Human genes 0.000 claims 1
- 101100388220 Caenorhabditis elegans adr-2 gene Proteins 0.000 claims 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
- 102100023471 E-selectin Human genes 0.000 claims 1
- 102100033398 Glutamate-cysteine ligase regulatory subunit Human genes 0.000 claims 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims 1
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 claims 1
- 102100028006 Heme oxygenase 1 Human genes 0.000 claims 1
- 101001062620 Homo sapiens Alpha-ketoglutarate-dependent dioxygenase FTO Proteins 0.000 claims 1
- 101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 claims 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 claims 1
- 101000870644 Homo sapiens Glutamate-cysteine ligase regulatory subunit Proteins 0.000 claims 1
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims 1
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 claims 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims 1
- 101001094647 Homo sapiens Serum paraoxonase/arylesterase 1 Proteins 0.000 claims 1
- 101000690425 Homo sapiens Type-1 angiotensin II receptor Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 102100029825 Leptin receptor gene-related protein Human genes 0.000 claims 1
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 claims 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 claims 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims 1
- 108700012920 TNF Proteins 0.000 claims 1
- 102100026803 Type-1 angiotensin II receptor Human genes 0.000 claims 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 1
- 108091006374 cAMP receptor proteins Proteins 0.000 claims 1
- 238000000249 far-infrared magnetic resonance spectroscopy Methods 0.000 claims 1
- 238000010339 medical test Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000036642 wellbeing Effects 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 101150059573 AGTR1 gene Proteins 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 2
- 101710104049 Cytochrome P450 1A1 Proteins 0.000 description 2
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 description 2
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 description 2
- 102000007648 Glutathione S-Transferase pi Human genes 0.000 description 2
- 108010007355 Glutathione S-Transferase pi Proteins 0.000 description 2
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 2
- 101000945357 Homo sapiens Collagen alpha-1(I) chain Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 2
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 2
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 102000005861 leptin receptors Human genes 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005184 men's health Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000037221 weight management Effects 0.000 description 2
- 230000005186 women's health Effects 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 102000000383 Alpha-Ketoglutarate-Dependent Dioxygenase FTO Human genes 0.000 description 1
- 108010016119 Alpha-Ketoglutarate-Dependent Dioxygenase FTO Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 101100337673 Caenorhabditis elegans gpx-1 gene Proteins 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 101710180981 Serum paraoxonase/arylesterase 1 Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 229940105772 coagulation factor vii Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Definitions
- the present invention relates to a method and system for determining an individual health intervention strategy. More particularly, this invention relates to a subject-specific health recommendation based on subject subjective and objective data, as well as a subject genetic profile.
- the present invention is directed to a method and system for determining an individual health intervention strategy.
- an embodiment of the present invention resides in a method of determining an individual health intervention strategy, the method including the steps of:
- evaluating the subjective data, the objective data and the genetic profile of the subject, and determining an individual health recommendation for the subject based on that data/profile is implemented by a computer.
- the evaluation and determination can be assisted by a decision support system implemented by a computer.
- an embodiment of the present invention resides in a system for determining an individual health intervention strategy, the system including:
- a memory coupled to a processor, wherein the memory includes computer- readable program code components configured to evaluate subject subjective data, subject objective data and a subject genetic profile, and determine an individual health recommendation for the subject based on the subjective data, objective data and genetic profile of the subject.
- an embodiment of the present invention resides in a computer-readable medium comprising the aforementioned computer-readable program code components for determining an individual health intervention strategy.
- FIG. 1 shows a flow diagram of a method of determining an individual health intervention strategy according to an embodiment of the present invention
- FIG. 2 shows a block diagram showing a system for determining an individual health intervention strategy according to an embodiment of the present invention.
- modules designed to achieve a beneficial personal health intervention strategy for a target individual, subject or client (including a perspective client).
- the modules are populated with a variety of data, including, for example, the results of various surveys or questionnaires completed by an individual, anthropometric (i.e., body) measurements, biometric test results, genetic profile, medical test results, and peer- reviewed scientific research, and provide various scores, results, profiles, and templates as outputs, including personalised health and wellness recommendations for an individual.
- the outputs can be displayed, for example, in either tabular format or in a graphical format.
- the surveys or questionnaires provide a convenient and efficient means whereby subjective data, in the form of responses to a variety of questions, may be collected from the target individual.
- the questions contained in the surveys or questionnaires may relate to, or be directed to, a variety of topics relevant to providing an individual health intervention strategy, and include, for example, questions concerning attitude, nutrition and diet, lifestyle, exercise, habits, preferences, work, stress, hobbies, personal health, personal/family health history, fitness, and goals.
- the questions in the surveys or questionnaires may be presented in a simple yes/no format or using a numerical score that allows a respondee to select between one or more extremes, or any other format familiar to one of skill in the art.
- exemplary surveys/questionnaires include: a lifestyle change readiness survey; a personal fitness plan survey; a current nutrition survey; a current exercise survey; a lifestyle choices survey; a personal health history survey; and a family health history survey.
- the anthropometric measurements provide a convenient and efficient means whereby objective data, in the form of results from a variety of body measurements, may be collected from the target individual.
- Anthropometric measurements or parameters include, but are not limited to, total body weight, height, body mass index
- BMI body fat, muscle mass, bone mass, visceral fat, percent water, and basal metabolic rate.
- Biometric tests include tests designed to quantitate one or more biological parameters, such as, for example, free radical activity and pH levels.
- a personal genetic profile of genes that impact fitness, health and wellness, and nutrition can be generated by a DNA testing laboratory using a biological sample from the target individual.
- the laboratory generates a genetic profile using, for example, one or more of the exemplary genes described herein, taking into account nominated single nucleotide polymorphism (SNP) variants based on the results of peer-reviewed scientific research.
- SNP single nucleotide polymorphism
- the test results are verified and assessed for quality control by a molecular geneticist.
- Medical test results are necessary to ensure that a target individual who is not fit for the intervention does not commence it.
- the medical test results provide an additional source of obj ective data concerning the target individual, and may take the form of reports from a medical practitioner based on one or more visits with the target individual, as well as laboratory data.
- laboratory data includes the results of one or more standard laboratory medical tests run on one or more subject/client samples ⁇ e.g., blood or urine), and includes, but is not limited to, LDL cholesterol levels, HDL cholesterol levels, total cholesterol levels, triglycerides levels, c-reactive protein levels, homocysteine levels, and fasting glucose levels.
- templates include, for example, a template containing scientific identification data associated with the genetic profile of genes that impact fitness, health and wellness, and nutrition. This genetic profile template has been assembled based on peer-reviewed scientific research in the field of human genetics, with genes selected because of the effects they have on the body at the cellular level.
- an additional exemplary template maps the genetic effects at the micro level to various effects on the whole body, such as, for example, obesity (and the ability to shed fat), blood pressure and heart function.
- This template associates these macro level effects with a corresponding individual health intervention strategy relating to, for example, weight management, cardiovascular health, women's health, men's health, healthy-ageing, improved health expectancy, improved life expectancy, and maintenance of cognitive function.
- Additional templates include nutrition, exercise and lifestyle intervention templates, based on peer-reviewed scientific research in the fields of human physiology and psychology, and take into account the genetic profile templates discussed above.
- the various scores, results and profiles generated as a result of the data (including subjective data, objective data and genetic data) used to populate the several modules described herein, along with the one or more templates as described, may be stored in an information storage device that is capable of communication through a computer network (e.g., the internet) with one or more users, such as, for example, the target individual, a scientific advisory team (or team member) or a consultant.
- a computer network e.g., the internet
- the modules disclosed herein include a Behavioural Change Module, a
- Phenotype Analysis Module a Genotype Analysis Module, a Medical Status Module, a Knowledge Management Module, and a Template Matching Module.
- This exercise can be viewed as a pre-qualifying step for the target individual to establish their: a) readiness to change, b) personal goals, c) level of confidence is achieving their goals, d) fitness history, e) current fitness destination, f) preferred activities and interests, and g) best time slots in a schedule (e.g., daily, weekly or monthly) in which to engage in the individualised health intervention.
- a schedule e.g., daily, weekly or monthly
- This information can be captured using the aforementioned surveys or questionnaires, and can be used to assess the target individual's commitment to making the necessary nutrition, exercise and lifestyle changes to improve their overall health and wellbeing. Such an assessment can be carried out, for example, by a health coach, a personal trainer, a consultant, or other qualified individual.
- a final aspect of this module is a determination by the target individual of an area of focus that matches their goals, and can include, for example, weight management, cardiovascular health, women's health, men's health, anti-ageing, improved health expectancy, improved life expectancy, maintenance of cognitive function, and combinations thereof.
- the Phenotype Analysis Module focuses on the target individual's current nutrition, exercise and lifestyle choices using the aforementioned surveys or questionnaires to collect data regarding the target individual's current health status. These surveys are designed to help identify any potential symptoms that indicate that the target individual's body is out-of-balance with regard to various physiological functions, such as, for example, inflammation at the cellular level, circulation problems and high levels of homocysteine.
- Survey results for this module are compared to one or more templates which list the association between the questions in the surveys/questionnaires and various functions.
- functions include, for example, physiological functions at the cellular level, such as, inflammation and free radical activity.
- This data can be analysed to assess the effects of the target individual's current nutrition, exercise and lifestyle choices on physiological functions in the body, such as cellular health. In addition, this analysis can help identify if the target individual is showing any adverse symptoms as a result of these effects at the cellular level.
- the data collected for this module can be used to establish the target individual's current phenotype.
- the collection of objective data from the target individual can be realised via anthropometric measurements and/or the completion of one or more biometric tests, as described herein, to further populate the data in this module.
- the Genotype Analysis Module is directed toward the determination of the target individual's personal genetic profile from a biological sample, such as, for example, a saliva sample or a mouth swab (for cheek epidermal cells).
- a biological sample such as, for example, a saliva sample or a mouth swab (for cheek epidermal cells).
- a genetic test panel consisting of multiple genes which influence fitness, health and wellness, and nutrition outcomes, and therefore have significant influence on a target individual's health and wellbeing, is generated.
- genes that can be analysed ⁇ e.g., for single nucleotide polymorphisms include, but are not limited to: Angiotensin I Converting Enzyme (ACE), Adiponectin (ADIPOQ), Adrenergic Receptor Beta-2 ( ⁇ ⁇ -2), Adrenergic Receptor Beta-3 (ADRP-3), Angiotensin Gene (AGT), Angiotensin II Receptor, Type 1 (AGTR1), Apolipoprotein A-I (APOA1), Catalase (CAT), Cystathionine- ⁇ - Synthase (CBS), Cholesteryl Ester Transfer Protein (CETP), Collagen, Type I, Alpha 1 (COL1A1), C-Reactive Protein (CRP), Cytochrome P450 1A1 (CYP1A1), Cytochrome P450 1B1 (CYP1B1), Endothelial Nitric Oxide Synthase (eNOS), Coagulation Factor VII (F7), Fat Mass and Obe
- a preferred method includes the following steps: a target individual provides a sample of their saliva using a DNA self collection kit; the DNA sample is sent to a DNA testing laboratory (preferably an accredited laboratory) for analysis; the laboratory generates a genetic profile using one or more of the exemplary genes listed herein, taking into account nominated SNP variants; the test results are verified and assessed for quality control by a molecular geneticist; the verified test results are analysed using one or more templates and presented in a personal genetic profile report.
- a DNA testing laboratory preferably an accredited laboratory
- Analysis of the target individual's medical status requires medical test data from the individual.
- the purpose of this module is to ensure a duty of care.
- Various bio-markers and possible medical risk factors of the target individual are analysed to determine their risk factor to undertake a personal health intervention, and also numerical values for the bio-markers are generated via one or more templates. This ensures that a target individual who is not fit for the intervention does not commence it.
- test data which includes medical reports from a medical practitioner and/or laboratory data, as described herein, may have been generated by a target individual's visit to a medical practitioner that is unrelated to their decision to pursue an individual health intervention strategy.
- the medical test data may be the result of a visit to a medical practitioner by a target individual wishing to undertake an individual health intervention strategy.
- the Knowledge Management Module allows one or more scientific advisors to maintain and update the various intervention templates used to analyse the subjective data, objective data and genetic data collected/received concerning the target individual, as well as to determine the appropriate individual health recommendation for the target individual. Maintenance of the various templates can be done at any time, and can also be done jointly or in isolation of each other.
- the output from all other modules is brought together in the Template Matching Module to perform the analysis necessary to generate an individual health recommendation for the target individual based on the subjective data, objective data and genetic data collected/received concerning the target individual.
- the gene variations for the target individual are analysed against the genetic templates to determine the intervention(s) they should apply, based on their genetic analysis. Determination of the appropriate intervention(s) is also affected by the target individual ' s subj ective and obj ective data, as interpreted via the appropriate nutrition, exercise and lifestyle templates.
- the output of this module is an individual health recommendation for the target individual, including one or more appropriate interventions, along with their individual weightings.
- the individual health recommendation can take the form of a personalised report, that includes one or more nutrient, exercise and lifestyle interventions for the target individual. It can also include one or more focus areas for the target individual, specifically directing the attention of the target individual to areas of nutrition, exercise and/or lifestyle that are a high priority for addressing.
- a method of determining an individual health intervention strategy 100 for a subject will now be described with reference to the general flow diagram shown in FIG. 1.
- the method includes at 110 collecting subject subjective data and at 120 collecting subject objective data.
- the method includes receiving additional subject objective data.
- the method of determining an individual health intervention strategy 100 for a subject further includes at 140 determining the subject's genetic profile.
- the method includes evaluating the subject subjective data, the subject objective data and the genetic profile of the subject.
- the method includes determining an individual health recommendation for the subject based on the subjective data, the objective data and the genetic profile of the subject.
- FIG. 2 shows a block diagram of a system 200 according to one aspect of the present invention.
- System 200 includes a computer in the form of a server 210 connected to a computer network 230, to which one or more users (also referred to as target individuals, subjects or clients (including perspective clients)) 220 have access. Users 220 may access the server 210 using a web browser, for example, on a computing device, such as a personal computer, laptop, server, personal digital assistant (PDA), mobile phone, and the like, as known by persons skilled in the art.
- the server 210 comprises computer-readable program code components for determining an individual health intervention strategy in accordance with the teachings of the present invention.
- the computer-readable program code components for determining an individual health intervention strategy in accordance with the teachings of the present invention can be on a user's computing device.
- Such computer-readable program code components are in the form of software installed on a memory, which comprises a computer-readable medium, such as a hard disk, a read only memory (e.g. , programmable read only memory (PROM), or electrically erasable programmable read only memory (EEPROM)), a random access memory (RAM) (e.g. , static random access memory (SRAM), or synchronous dynamic random access memory (SDRAM)), or hybrid memory (e.g., FLASH), or other types of memory as are well known in the art.
- a computer-readable medium such as a hard disk, a read only memory (e.g. , programmable read only memory (PROM), or electrically erasable programmable read only memory (EEPROM)), a random access memory (RAM) (e.g. , static random access memory (SRAM), or
- the computer-readable program code components are then processed by a processor in communication with the memory and are configured to cause execution of a method of the present invention.
- a database stored on the server 210, interacts with a website as would be known to a person skilled in the art.
- the database stores profiles of users 220, as well as subjective data, objective data and genetic profiles of users 220, and one or more templates against which the subjective data, objective data and genetic profiles of users 220 is compared.
- User profiles include individual-specific details pertaining to a user 220 of the website.
- a database stored on a user's computing device which may interact with the server 210 via the computer network 230 and/or the website of the system 200, can also store profiles of one or more users 220, as well as subjective data, objective data and genetic profiles of one or more users 220, and one or more templates against which the subjective data, objective data and genetic profiles of one or more users 220 is compared.
- the website of the system 200 allows an individual from the plurality of users 220 to receive an individual health recommendation for the user based on the subjective data, objective data and genetic profiles of the user 220.
- the recommendation is determined by the system 200 according to the method of the present invention.
- the website may also provide links to manufacturers one or more products of use to users 220 as they implement a health intervention strategy.
- the method and system disclosed above have as an advantage a multidimensional approach to improving health and wellness outcomes in individuals based on individual-specific subjective and objective data, as well as an individual-specific genetic profile.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
L'invention concerne un procédé et un système permettant d'établir une stratégie personnelle d'intervention sur la santé et, plus particulièrement, un procédé et un système permettant d'établir une recommandation sur la santé propre à un sujet compte tenu de données subjectives et objectives relatives au sujet, ainsi que d'un profil génétique du sujet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010903112A AU2010903112A0 (en) | 2010-07-13 | System and method for determining personal health intervention | |
AU2010903112 | 2010-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012006669A1 true WO2012006669A1 (fr) | 2012-01-19 |
Family
ID=45468805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2011/000881 WO2012006669A1 (fr) | 2010-07-13 | 2011-07-13 | Système et procédé permettant d'établir une stratégie personnelle d'intervention sur la santé |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012006669A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016005793A1 (fr) * | 2014-07-09 | 2016-01-14 | Suisse Life Science S.A. | Procédé cosmétique. |
CN110494880A (zh) * | 2017-01-27 | 2019-11-22 | 欧瑞3恩公司 | 基于个人基因轮廓来判定和展现购买建议的系统和方法 |
US10678890B2 (en) | 2015-08-06 | 2020-06-09 | Microsoft Technology Licensing, Llc | Client computing device health-related suggestions |
CN112472052A (zh) * | 2020-12-21 | 2021-03-12 | 安徽华米智能科技有限公司 | 基于个人运动机能指数pai的体重预测方法、装置和设备 |
US11244752B2 (en) | 2016-10-24 | 2022-02-08 | Nederlandse Organisatie Voor Toegepast—Natuurwetenschappelijk Onderzoek Tno | System and method for implementing meal selection based on vitals, genotype and phenotype |
US11545250B2 (en) | 2020-03-20 | 2023-01-03 | Kpn Innovations, Llc. | Methods and systems for generating lifestyle change recommendations based on biological extractions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008067551A2 (fr) * | 2006-11-30 | 2008-06-05 | Navigenics Inc. | Procédés et systèmes d'analyse génétique |
US7650290B2 (en) * | 2004-09-15 | 2010-01-19 | Coenrad Karel Van Kalken | Computer installation for establishing a diagnosis |
-
2011
- 2011-07-13 WO PCT/AU2011/000881 patent/WO2012006669A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7650290B2 (en) * | 2004-09-15 | 2010-01-19 | Coenrad Karel Van Kalken | Computer installation for establishing a diagnosis |
WO2008067551A2 (fr) * | 2006-11-30 | 2008-06-05 | Navigenics Inc. | Procédés et systèmes d'analyse génétique |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016005793A1 (fr) * | 2014-07-09 | 2016-01-14 | Suisse Life Science S.A. | Procédé cosmétique. |
US10678890B2 (en) | 2015-08-06 | 2020-06-09 | Microsoft Technology Licensing, Llc | Client computing device health-related suggestions |
US11244752B2 (en) | 2016-10-24 | 2022-02-08 | Nederlandse Organisatie Voor Toegepast—Natuurwetenschappelijk Onderzoek Tno | System and method for implementing meal selection based on vitals, genotype and phenotype |
CN110494880A (zh) * | 2017-01-27 | 2019-11-22 | 欧瑞3恩公司 | 基于个人基因轮廓来判定和展现购买建议的系统和方法 |
US11545250B2 (en) | 2020-03-20 | 2023-01-03 | Kpn Innovations, Llc. | Methods and systems for generating lifestyle change recommendations based on biological extractions |
CN112472052A (zh) * | 2020-12-21 | 2021-03-12 | 安徽华米智能科技有限公司 | 基于个人运动机能指数pai的体重预测方法、装置和设备 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11461664B2 (en) | Methods and systems for an artificial intelligence alimentary professional support network for vibrant constitutional guidance | |
Wolf et al. | Development and validation of the consumer health activation index | |
Morren et al. | Perceived genetic knowledge, attitudes towards genetic testing, and the relationship between these among patients with a chronic disease | |
US10553319B1 (en) | Artificial intelligence systems and methods for vibrant constitutional guidance | |
Christensen et al. | A Danish population-based twin study on general health in the elderly | |
Chauhan et al. | A meta-analysis of e-health applications acceptance: Moderating impact of user types and e-health application types | |
Rosen | Improving quality in the changing world of primary care | |
KR20140119022A (ko) | 체중 및 영양 제어를 위한 유전자 기반 건강 관리 시스템들 | |
KR102258899B1 (ko) | 통합적 건강 정보를 이용한 식단 및 운동 추천 방법 및 서비스 시스템 | |
US11581094B2 (en) | Methods and systems for generating a descriptor trail using artificial intelligence | |
WO2012006669A1 (fr) | Système et procédé permettant d'établir une stratégie personnelle d'intervention sur la santé | |
US11937939B2 (en) | Methods and systems for utilizing diagnostics for informed vibrant constituional guidance | |
Medendorp et al. | Communication skills training for healthcare professionals in providing genetic counseling: A scoping literature review | |
KR102261270B1 (ko) | 사용자 다중 특징 정보를 이용한 개인 맞춤형 콘텐츠 제공 방법 및 분석장치 | |
Almagharbeh | The impact of AI‐based decision support systems on nursing workflows in critical care units | |
Reis et al. | Aggregation of qualitative studies—From theory to practice: Patient priorities and family medicine/general practice evaluations | |
Floyd et al. | Cumulative risk on the oxytocin receptor gene (OXTR) predicts empathic communication by physician assistant students | |
CA3121058A1 (fr) | Methode d'utilisation de profils de biomarqueurs jumeaux numeriques pour ameliorer l'entrainement et la performance sportifs, le mieux-etre et les resultats de soins de sante | |
Bernhardt | Genetic counselors and the future of clinical genomics | |
Safarova et al. | A call for training programmes in cardiovascular genomics | |
KR20210145539A (ko) | 마이크로바이옴을 이용한 건강 정보 제공 방법 및 분석장치 | |
Garcia et al. | Time-varying proportional odds model for mega-analysis of clustered event times | |
Bartol | Re-examining the gene in personalized genomics | |
Robleto et al. | Medical students’ perceptions of an artificial intelligence (AI) assisted diagnosing program | |
Powers et al. | The Cholesterol, Hypertension, and Glucose Education (CHANGE) study for African Americans with diabetes: study design and methodology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11806137 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11806137 Country of ref document: EP Kind code of ref document: A1 |